Bernstein Downgrades Summit Therapeutics to Underperform
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Stocks · News reference
Summit Therapeutics is awaiting a critical FDA decision regarding its investigational cancer drug, ivonescimab, for the treatment of advanced non-small cell lung cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Filed: 2026-11-18 AccNo: 0001599298-26-000094 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Summit Therapeutics has launched the HARMONi-10 global Phase III clinical trial to evaluate ivonescimab as a consolidation therapy for patients with unresectable Stage III non-small cell lung cancer.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.